Drugs / Subutinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01806376 | Mar 2013 → Sep 2014 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Subutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01806376 ↗ |
| Known as | Subutinib Maleate | “Test drug: Subutinib Maleate capsules” NCT01806376 ↗ |
| Route | Oral | “oral Subutinib Maleate capsules” NCT01806376 ↗ |